Overview

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine if the opioid properties of ketamine are responsible for its antidepressant effects. Since naltrexone can block opiate actions, the investigators will determine if naltrexone can effectively block ketamine's effects.
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Collaborator:
Schatzberg, Alan, M.D.
Treatments:
Ketamine
Naltrexone